Watchlist Price Alert

Embecta Corp. (EMBC)

NASDAQ: EMBC · Real-Time Price · USD

10.71

0.21 (1.95%)

At close: May 23, 2025, 3:59 PM

10.83

1.12%

After-hours: May 23, 2025, 04:39 PM EDT

1.95% (1D)

Bid	10.83
Market Cap	625.92M
Revenue (ttm)	1.08B
Net Income (ttm)	52.1M
EPS (ttm)	0.89
PE Ratio (ttm)	12.03
Forward PE	3.62
Analyst	Hold

Ask	10.99
Volume	692,406
Avg. Volume (20D)	620,796
Open	10.40
Previous Close	10.51
Day's Range	10.33 - 10.78
52-Week Range	10.27 - 21.48
Beta	1.19

About EMBC

undefined

[Read more]

Industry n/a

Sector n/a

IPO Date n/a

Employees NaN

Stock Exchange n/a

Ticker Symbol EMBC

Website n/a

Full Company Profile

Analyst Forecast

According to 0 analyst ratings, the average rating for EMBC stock is "n/a." The 12-month stock price forecast is $n/a, which is a decrease of 0% from the latest price.

Stock Forecasts

Why Price Moved

2 weeks ago

-10%

Embecta shares are trading lower. The company repo... Unlock content with Pro Subscription

6 months ago

+29.77%

Embecta shares are trading higher after the company reported better-than-expected Q4 financial results and issued FY25 adjusted EPS guidance above estimates.

News

2 weeks ago · seekingalpha.com

Embecta Corp. (EMBC) Q2 2025 Earnings Call Transcript

Embecta Corp. (NASDAQ:EMBC ) Q2 2025 Earnings Conference Call May 9, 2025 8:00 AM ET Company Participants Dev Kurdikar - President & CEO Jake Elguicze - CFO Pravesh Khandelwal - Vice VP, IR Conference...

2 weeks ago · zacks.com

Embecta Corp. (EMBC) Tops Q2 Earnings Estimates

Embecta Corp. (EMBC) came out with quarterly earnings of $0.70 per share, beating the Zacks Consensus Estimate of $0.66 per share. This compares to earnings of $0.67 per share a year ago.

2 months ago · seekingalpha.com

Embecta: Weak Outlook But Mouth-Watering Valuation Skew Risk-Reward In Favour

Embecta faces headwinds from new insulin delivery technologies and GLP-1 drugs, but its valuation is compelling with a ~44% free cash flow yield on guided free cashflow. EMBC's end market is expected ...